Opinion

Stephen V Liu Highlighted CANOPY-N Phase 2 Study in Stage IB–IIIA NSCLC

Stephen V Liu/X

Jun 15, 2025, 02:23

Stephen V Liu Highlighted CANOPY-N Phase 2 Study in Stage IB–IIIA NSCLC

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Results from negative phase 2 CANOPY-N trial, JTO.

Patients with resectable NSCLC randomized to neoadjuvant canakinumab (anti IL-1β), pembrolizumab, or both. Canakinumab MPR 3%, pembro MPR 17%, combo MPR 17%.

Disappointing but glad results published.”

Title: CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

Journal: JTO

Authors: Jay M. Lee, Jean-Louis Pujol, Jun Zhang, Oleg Leonov, Masahiro Tsuboi, Edward S. Kim, Calvin Ng, Nicolas Moreno, Amy Cummings, Ilhan Hacibekiroglu, Abidin Sehitogullari, Nirmal Veeramachaneni, Cathy Spillane, Jiawei Duan, Claudia Bossen, Alexander Savchenko, Chiara Lobetti-Bodoni, Tony Mok, Pilar Garrido

Read the full article.

CANOPY-N

More posts featuring Stephen V Liu on OncoDaily.

Abidin Sehitogullari Alexander Savchenko Amy Cummings Calvin Ng Canakinumab cancer CANOPY-N Cathy Spillane Chiara Lobetti-Bodoni Claudia Bossen Edward S. Kim Georgetown University Ilhan Hacibekiroglu Jay M. Lee Jean-Louis Pujol Jiawei Duan JTO Jun Zhang Masahiro Tsuboi Nicolas Moreno Nirmal Veeramachaneni NSCLC Oleg Leonov OncoDaily Oncology pembrolizumab Pilar Garrido Stephen V Liu Tony Mok

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing

Vinay Prasad Rejoins FDA Days After Exit